newsfilter
← Latest News
GlobeNewswire·

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world